Literature DB >> 21513712

Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs?

K C M Santegoets1, L van Bon, W B van den Berg, M H Wenink, T R D J Radstake.   

Abstract

In the last decade Toll-like receptor (TLR) research has led to new insights in the pathogenesis of many rheumatic diseases. In autoimmune diseases like systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis TLR signaling is likely to be involved in tolerance breakthrough and chronic inflammation via combined Fc gamma receptors and TLR recognition of immune complexes. Furthermore, inflammatory diseases like psoriatic arthritis and gout also show more and more evidence for TLR involvement. In this review we will discuss the involvement of TLR signaling in several rheumatic diseases and stress their similarities and differences based on recent findings.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21513712     DOI： 10.1016/j.febslet.2011.04.028

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  Negative regulation of TLR signaling in myeloid cells--implications for autoimmune diseases.

Authors:  Jessica A Hamerman; Jessica Pottle; Minjian Ni; Yantao He; Zhong-Yin Zhang; Jane H Buckner
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

Review 2.  Toll-Like Receptor Pathways in Autoimmune Diseases.

Authors:  Ji-Qing Chen; Peter Szodoray; Margit Zeher
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 3.  Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis.

Authors:  DeLisa Fairweather; Michelle A Petri; Michael J Coronado; Leslie T Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

Review 4.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

Review 5.  Immunological biomarkers in dermatomyositis.

Authors:  Jeannette M Olazagasti; Timothy B Niewold; Ann M Reed
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

6.  Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.

Authors:  Tamer A Gheita; Safaa Sayed; Gada S Azkalany; Nouran Abaza; Nevin Hammam; A H Eissa
Journal:  Clin Rheumatol       Date:  2017-10-26       Impact factor: 2.980

7.  Exposure to Candida albicans polarizes a T-cell driven arthritis model towards Th17 responses, resulting in a more destructive arthritis.

Authors:  Renoud J Marijnissen; Marije I Koenders; Frank L van de Veerdonk; John Dulos; Mihai G Netea; Annemieke M H Boots; Leo A B Joosten; Wim B van den Berg
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

8.  Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.

Authors:  A Paradowska-Gorycka; A Wajda; B Stypinska; E Walczuk; E Rzeszotarska; M Walczyk; E Haladyj; K Romanowska-Prochnicka; A Felis-Giemza; A Lewandowska; M Olesińska
Journal:  Clin Exp Immunol       Date:  2021-01-17       Impact factor: 5.732

Review 9.  The Telomere/Telomerase System in Chronic Inflammatory Diseases. Cause or Effect?

Authors:  Vasileios Kordinas; Anastasios Ioannidis; Stylianos Chatzipanagiotou
Journal:  Genes (Basel)       Date:  2016-09-03       Impact factor: 4.096

10.  Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Authors:  Cheng Liao; Jonathan Hsu; Yong Kim; Dong-Qing Hu; Daigen Xu; Jun Zhang; Achal Pashine; John Menke; Toni Whittard; Natasha Romero; Theresa Truitt; Michelle Slade; Christine Lukacs; Johannes Hermann; Mingyan Zhou; Matthew Lucas; Satwant Narula; Julie DeMartino; Seng-Lai Tan
Journal:  Arthritis Res Ther       Date:  2013-10-04       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.